January 29, 2008 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, announced the initiation of patient dosing in clinical protocol TPI ASM8-205, a Phase 2 safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe, including the UK, Netherlands, France and Italy. TPI ASM8 is a novel, inhaled anti-inflammatory, RNA-targeting drug intended for the management of moderate to severe asthma... [PDF] TOPIGEN's Press Release-Feb 14, 2008
TOPIGEN's TPI ASM8 , European Phase 2 Clinical Study of TPI ASM8 in Patients With Asthma
January 29, 2008 - TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, announced the initiation of patient dosing in clinical protocol TPI ASM8-205, a Phase 2 safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. This study builds on prior pharmacodynamic and safety data in a three-day study of TPI ASM8 in an allergen challenge model and will be conducted in collaboration with leading clinical research centers across Europe, including the UK, Netherlands, France and Italy. TPI ASM8 is a novel, inhaled anti-inflammatory, RNA-targeting drug intended for the management of moderate to severe asthma... [PDF] TOPIGEN's Press Release-
